Precision for Medicine, a biomarker-driven clinical research and development services organisation, announced on Wednesday the opening of its new office in Japan.

The new Tokyo office strengthens Precision's local partnerships, regulatory alignment and global integrations in the world's third largest pharmaceutical market. It positions Precision to work directly with biopharmaceutical sponsors, investigators, key external experts and sites, enabling more agile operational delivery and stronger collaborations across Japan's research ecosystem.

James Cheong, Precision's senior vice president, APAC, said: "Japan is a vital component of global clinical development. By establishing our own office with dedicated leadership, we eliminate the gap between global trial design and Japanese regulatory expectations, offering our clients consistent global standards with the confidence that comes from genuine local presence."

The new office complements Precision's existing APAC footprint, which includes over 500 employees and offices in Singapore, Mainland China, Hong Kong, India, South Korea, Taiwan and Australia.